Sovenyr Get early access

Signal2026-07-30

EPO Patents

[EPO] TOLERIZING IMMUNOMODULATORY COMBINATION

Part of

Engineered T Cell Immunotherapy Advances

Open primary source See the whole picture

Powered by Sovenyr — cross-source signal intelligence. Figures are collected data as-dated, not investment advice.